Published in Biometrics on August 10, 2009
Adaptive randomization to improve utility-based dose-finding with bivariate ordinal outcomes. J Biopharm Stat (2012) 1.23
Adaptive designs for dual-agent phase I dose-escalation studies. Nat Rev Clin Oncol (2013) 1.04
Continual reassessment and related designs in dose-finding studies. Stat Med (2011) 0.93
Optimizing the concentration and bolus of a drug delivered by continuous infusion. Biometrics (2011) 0.92
Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials. Ann Oncol (2015) 0.85
Escalation strategies for combination therapy Phase I trials. Pharm Stat (2012) 0.84
Challenges in the evaluation, consent, ethics and history of early clinical trials - Implications of the Tuskegee 'trial' for safer and more ethical clinical trials. Curr Opin Mol Ther (2009) 0.81
Simple benchmark for complex dose finding studies. Biometrics (2014) 0.79
Rejoinder to comments on Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer. J Am Stat Assoc (2012) 0.79
A robust Bayesian dose-finding design for phase I/II clinical trials. Biostatistics (2015) 0.78
Optimizing Sedative Dose in Preterm Infants Undergoing Treatment for Respiratory Distress Syndrome. J Am Stat Assoc (2014) 0.77
Parametric Dose Standardization for Optimizing Two-Agent Combinations in a Phase I-II Trial with Ordinal Outcomes. J R Stat Soc Ser C Appl Stat (2016) 0.75
A Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities. Bayesian Anal (2013) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics (1990) 10.19
A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care (1986) 7.26
Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics (2000) 5.50
Design and analysis of phase I clinical trials. Biometrics (1989) 4.31
Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med (1998) 4.19
Dose-finding based on efficacy-toxicity trade-offs. Biometrics (2004) 3.46
The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes. Control Clin Trials (2002) 2.27
Dose-finding with two agents in Phase I oncology trials. Biometrics (2003) 2.23
Dose-finding designs for HIV studies. Biometrics (2001) 2.22
The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach. Biometrics (2007) 2.07
A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics (1998) 1.90
A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial. Biometrics (2005) 1.64
Simultaneously optimizing dose and schedule of a new cytotoxic agent. Clin Trials (2007) 1.46
A new dose-finding design for bivariate outcomes. Biometrics (2003) 1.40
Bivariate isotonic design for dose-finding with ordered groups. Stat Med (2006) 1.32
An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. Stat Med (2007) 1.29
Patient-specific dose finding based on bivariate outcomes and covariates. Biometrics (2008) 1.24
Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials. J Clin Oncol (1993) 1.20
Recent developments in adaptive designs for Phase I/II dose-finding studies. J Biopharm Stat (2007) 1.11
Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations. J Biopharm Stat (2006) 1.11
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA (2010) 5.04
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol (2007) 3.79
Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr (2009) 3.41
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol (2009) 2.88
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol (2013) 2.39
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst (2009) 2.34
Continuous Bayesian adaptive randomization based on event times with covariates. Stat Med (2006) 2.30
Visceral pleural invasion is not predictive of survival in patients with lung cancer and smaller tumor size. Ann Thorac Surg (2013) 2.15
Impact of RNA degradation on gene expression profiles: assessment of different methods to reliably determine RNA quality. J Biotechnol (2006) 2.12
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol (2004) 2.10
Severe mental illness at ART initiation is associated with worse retention in care among HIV-infected Ugandan adults. Trop Med Int Health (2012) 2.08
Carriage of methicillin-resistant Staphylococcus aureus in home care settings: prevalence, duration, and transmission to household members. Arch Intern Med (2009) 2.07
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant (2008) 1.96
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst (2013) 1.90
Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature. Eur J Cancer (2011) 1.85
Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys (2012) 1.83
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol (2002) 1.79
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol (2011) 1.78
High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation (2009) 1.76
Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol (2003) 1.75
Determining the effective sample size of a parametric prior. Biometrics (2007) 1.74
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant (2002) 1.71
Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer. Radiother Oncol (2013) 1.68
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol (2010) 1.68
Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol (2009) 1.68
Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol (2004) 1.67
Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys (2012) 1.65
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol (2007) 1.63
Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood (2011) 1.61
Continual reassessment method for ordered groups. Biometrics (2003) 1.60
Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol (2012) 1.59
Association of antiretroviral therapy adherence and health care costs. Ann Intern Med (2010) 1.57
Increased estrogen receptor betacx expression during mammary carcinogenesis. Clin Cancer Res (2005) 1.56
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant (2005) 1.55
Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res (2013) 1.53
New designs for phase 2 clinical trials. Blood (2003) 1.53
Breast cancer risk in relation to abortion: Results from the EPIC study. Int J Cancer (2006) 1.51
Regulation of peritoneal and systemic neutrophil-derived tumor necrosis factor-alpha release in patients with severe peritonitis: role of tumor necrosis factor-alpha converting enzyme cleavage. Crit Care Med (2005) 1.51
Non-parametric optimal design in dose finding studies. Biostatistics (2002) 1.51
Antidepressant medication augmented with cognitive-behavioral therapy for generalized anxiety disorder in older adults. Am J Psychiatry (2013) 1.50
Leukocyte activation: the link between inflammation and coagulation during heatstroke. A study of patients during the 2003 heat wave in Paris. Crit Care Med (2008) 1.50
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol (2010) 1.49
Monitoring late-onset toxicities in phase I trials using predicted risks. Biostatistics (2007) 1.48
Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol (2011) 1.48
Simultaneously optimizing dose and schedule of a new cytotoxic agent. Clin Trials (2007) 1.46
UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res (2007) 1.43
Survival end point reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol (2008) 1.41
Using medical screening examinations to reduce emergency department overcrowding. J Emerg Nurs (2008) 1.41
Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol (2004) 1.41
Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol (2002) 1.40
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant (2010) 1.34
CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients. Clin Cancer Res (2005) 1.32
Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin Cancer Res (2008) 1.30
Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res (2004) 1.25
Determining a maximum-tolerated schedule of a cytotoxic agent. Biometrics (2005) 1.24
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer (2013) 1.24
Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program). Eur Heart J (2012) 1.23
Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res (2009) 1.23
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol (2010) 1.22
Life-expectancy of patients enrolled in phase 1 clinical trials: a systematic review of published prognostic models. Crit Rev Oncol Hematol (2012) 1.18
Function of Wnt/β-catenin in counteracting Tcf3 repression through the Tcf3-β-catenin interaction. Development (2012) 1.17
Accounting for patient heterogeneity in phase II clinical trials. Stat Med (2008) 1.15
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant (2009) 1.14
Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. Target Oncol (2012) 1.13
Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer. J Am Stat Assoc (2012) 1.11
Successful long-term program for controlling methicillin-resistant Staphylococcus aureus in intensive care units. Intensive Care Med (2005) 1.11
Molecular epidemiology of hepatitis C virus in a social network of injection drug users. J Infect Dis (2004) 1.11
Seamlessly expanding a randomized phase II trial to phase III. Biometrics (2002) 1.11
Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival. Clin Cancer Res (2004) 1.09
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist (2011) 1.09
Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. Qual Life Res (2008) 1.08
The ETS protein MEF is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2. Mol Cell Biol (2006) 1.07
Noncatalytic requirement for cyclin A-cdk2 in p27 turnover. Mol Cell Biol (2004) 1.06
Imprinted genes that regulate early mammalian growth are coexpressed in somatic stem cells. PLoS One (2011) 1.06
Breast imaging: understanding how accuracy is measured when lesion are the unit of analysis. Breast J (2013) 1.05
Bayesian adaptive model selection for optimizing group sequential clinical trials. Stat Med (2008) 1.03
Deletion of Porcn in mice leads to multiple developmental defects and models human focal dermal hypoplasia (Goltz syndrome). PLoS One (2012) 1.02
Improved outcomes for lap-banding using the Insuflow device compared with heated-only gas. JSLS (2009) 1.01
Prognostic factors affecting local control of hepatic tumors treated by Stereotactic Body Radiation Therapy. Radiat Oncol (2012) 1.01
Sensitivity analysis when data are missing not-at-random. Epidemiology (2011) 1.01
Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015). Int J Radiat Oncol Biol Phys (2010) 1.00
Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: a population-based study. Cancer (2012) 0.99
Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. Clin Cancer Res (2007) 0.99
Evaluating Joint Effects of Induction-Salvage Treatment Regimes on Overall Survival in Acute Leukemia. J R Stat Soc Ser C Appl Stat (2013) 0.98
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res (2004) 0.98
Prior Effective Sample Size in Conditionally Independent Hierarchical Models. Bayesian Anal (2012) 0.98
Perceptions of children's body sizes among mothers living on the Texas-Mexico border (La Frontera). Public Health Nurs (2006) 0.96
Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics. Stat Biosci (2010) 0.96
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol (2008) 0.96
Foxp1 maintains hair follicle stem cell quiescence through regulation of Fgf18. Development (2013) 0.96
Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant (2010) 0.95
Monitoring the rates of composite events with censored data in phase II clinical trials. Biometrics (2002) 0.95
Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen. J Clin Oncol (2005) 0.95